ATIC

07/10/2026

ATIC are delighted to welcome Dr Shivani Patel to the October Beyond Insulin seminar. Dr Patel will present her work on elucidating the phenotype of autoantibody negative type 1 diabetes. All the details and the registration link are below. We look forward to seeing you there!

Seminar 34, Beyond Insulin Seminar Series - Dr Shivani Patel presents elucidating the phenotype of autoantibody negative type 1 diabetes.

07/10/2026

Limited places remain for people living with type 1 diabetes to participate in this clinical trial. Please reach out to our friendly team who can provide further information if you are interested. You can reach out via our website: atic.svi.edu.au or via email: [email protected]

04/10/2026

There are places remaining for children and teenagers with newly diagnosed type 1 diabetes to take part in a clinical trial. The SAFEGUARD trial is testing a new treatment that hopes to protect the body's ability to make insulin. This trial is open to 5-17 year old across Australia and New Zealand. Our friendly team would be delighted to provide further information and answer any questions that you might have. You can contact us via email: [email protected] or express interest via our website: atic.svi.edu.au

26/09/2026

23/09/2026

Could screening change the future of type 1 diabetes?
By finding T1D before symptoms appear, screening can help identify people who may benefit from monitoring and treatments being studied to delay progression.
Screening for type 1 diabetes is available for all Australians over 1 year of age. Register now at type1screen.org

Screen today. Know more. Explore what’s possible.

13/09/2026

We are looking for more people living with T1D to participate in this clinical trial! If you (or someone you know!) have type 1 diabetes and would like to contribute to advancing research in this space, please reach out via our website: atic.svi.edu.au or via email: [email protected]

03/09/2026

Breaking News! The SAFEGUARD trial is now seeking children and teens (aged 5-17) who are newly diagnosed with type 1 diabetes to participate in a clinical trial that aims to protect the body's ability to make insulin!
We have clinical trial sites across Australia and New Zealand.
More information is available on our website: atic.svi.edu.au/clinical-trials or you can contact our friendly team via email [email protected]

31/08/2026

Remember our BANDIT study? 💙
BANDIT showed that baricitinib, an immunotherapy drug, could help protect the insulin-producing beta cells in people recently diagnosed with type 1 diabetes. People who took baricitinib for 48 weeks were able to keep producing more of their own insulin and needed less injected insulin than those who received placebo. This new follow-up study asked an important question: what happens after treatment stops?
You can read more here:

Further results from the BANDIT study have been published in Diabetes Care.

25/08/2026

Are you an adult living with type 1 diabetes who is interested in taking part in the research of a new treatment?
The MT101-101 study is now available in Melbourne, Brisbane and the Gold Coast. There are more details available on the ATIC website (atic.svi.edu.au/clinical-trials/) or contact us using the details in the image. Our friendly team look forward to hearing from you. 😊

13/08/2026

Team ATIC are looking forward to being at the IDF-WPR/ADC 2026 combined congress next week in Melbourne. We will be exhibiting in the Breakthrough T1D Australia booth (booth 112) and we are looking forward to a week of learning, sharing and collaborating. We're excited to meet those of you that will be there too - please come and say hello!